Start Publications Supramolecular Control in Nanostructured Film Architectures for ...
KSV NIMA

Supramolecular Control in Nanostructured Film Architectures for Detecting Breast Cancer

Year: 2015

Journal: ACS APPLIED MATERIALS & INTERFACES, Vol. 7, p 11833-11841, 20170208

Authors: Soares, Juliana Coatrini; Shimizu, Flavio Makoto; Soares, Andrey Coatrini; Caseli, Luciano; Ferreira, Jacqueline; Oliveira, Osvaldo N., Jr.

Organizations: Univ Sao Paulo, Sao Carlos Inst Phys, BR-13560970 Sao Paulo, Brazil; Univ Fed Sao Paulo, Inst Environm Chem & Pharmaceut Sci, BR-09972970 Sao Paulo, Brazil; Univ Fed Rio Grande do Sul, Inst Chem, BR-91501970 Porto Alegre, RS, Brazil

The need for early detection of various diseases, including breast cancer, has motivated research into nanomaterials that can be assembled in organized films which serve as biosensors. Owing to the variety of possible materials and film architectures, procedures are required to design optimized biosensors. In this study, we combine surface-specific methods to monitor the assembly of antibodies on nanostructured films with two distinct architectures. In the first, a layer of the antibody type mouse anti-HER2 (clone tab250) was immobilized on a self-assembled monolayer (SAM) of 11-mercaptoundecanoic acid modified with N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC). In the second approach, a SAM of cysteamine was coated with a biotin/spreptavidin bilayer on which a layer of biotinylated antibody type MSx2HUp185/her biotin was adsorbed. The rougher, less passivating coating with cysteamine determined from cyclic voltammetry and scanning electron microscopy led to biosensors that are more sensitive to detect the breast cancer ERBB2 (HER2) biomarker in impedance spectroscopy measurements. This higher distinguishing ability of the cysteamine-containing film architecture was proven with information visualization methods to treat the impedance data. Polarization-modulated infrared reflection absorption spectroscopy (PM-IRRAS) confirmed that biosensing resulted from the antibody-ERBB2 antigen affinity.